Capital Investment Advisors LLC Has $14.01 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

Capital Investment Advisors LLC decreased its holdings in Bristol-Myers Squibb (NYSE:BMY) by 7.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,731 shares of the biopharmaceutical company’s stock after selling 18,061 shares during the period. Capital Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $14,011,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Meridian Financial Partners LLC acquired a new position in Bristol-Myers Squibb in the 1st quarter valued at approximately $211,000. Park Avenue Securities LLC grew its holdings in shares of Bristol-Myers Squibb by 17.6% during the 1st quarter. Park Avenue Securities LLC now owns 66,779 shares of the biopharmaceutical company’s stock valued at $4,073,000 after acquiring an additional 9,973 shares in the last quarter. SOA Wealth Advisors LLC. increased its stake in shares of Bristol-Myers Squibb by 7.5% in the first quarter. SOA Wealth Advisors LLC. now owns 5,036 shares of the biopharmaceutical company’s stock worth $307,000 after acquiring an additional 353 shares during the last quarter. KMG Fiduciary Partners LLC raised its holdings in shares of Bristol-Myers Squibb by 11.9% during the first quarter. KMG Fiduciary Partners LLC now owns 39,403 shares of the biopharmaceutical company’s stock worth $2,403,000 after acquiring an additional 4,193 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in Bristol-Myers Squibb by 6.6% during the first quarter. Patriot Financial Group Insurance Agency LLC now owns 5,303 shares of the biopharmaceutical company’s stock valued at $323,000 after purchasing an additional 328 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction that occurred on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Argus raised Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Jefferies Financial Group cut their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Wednesday, April 23rd. Wall Street Zen cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 target price (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $58.00.

Bristol-Myers Squibb Trading Up 1.2%

Bristol-Myers Squibb stock opened at $48.42 on Friday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. The firm has a market capitalization of $98.54 billion, a PE ratio of -10.95, a PEG ratio of 2.07 and a beta of 0.38. The business’s 50-day simple moving average is $49.34 and its 200-day simple moving average is $55.04.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned ($4.40) earnings per share. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.